### Company Profile

**Industry Sector:** Medical Devices

**Company Overview:** Healionics was founded in Seattle, WA in 2007 to commercialize a new synthetic porous tissue scaffold – STAR® Biomaterial – that overcomes biocompatibility and infection problems of implantable devices.

**Target Market(s):** Advanced wound care, aesthetic medicine, cardiovascular surgery, diabetes, general surgery, ophthalmology, pain management, regenerative medicine, urological/women’s health.

### Key Value Drivers

**Technology**: Our patented STAR® (Sphere Templated Angiogenic Regeneration) biomaterial consists of a precisely-sized, open-pore 3D scaffold. Its optimized geometry maximizes macrophage concentration, thereby achieving its distinctive biological effects of being anti-fibrotic, angiogenic, and anti-infective -- with no need for added growth factors, drugs or other treatments.

**Competitive Advantage**: Conventional synthetic grafts typically fail due to neointimal hyperplasia which leads to lumen blockage. This is promoted by the fibrous capsule which forms around the graft, causing compliance mismatch with the natural vessel. In contrast, STARgraft is the only synthetic graft that prevents fibrotic encapsulation, so that the graft wall retains flexibility.

**Plan & Strategy**: STAR has been specifically engineered for the purpose of enhancing biointegration and promoting healing.

### Management

**Leadership:** Mike Connolly, CEO; Max Maginness, Ph.D. President & COO; Andrew Marshall, Ph.D. Director & CTO.

**Scientific Advisory Board:** Buddy Ratner, Ph.D.; Andrew Branca, Ph.D.; James Bryers, Ph.D; Henri Gaboriau, MD; Arthur Golding, MD; Sam Naficy, MD; Miqin Zhang, Ph.D.

### Product Pipeline

**Pipeline:** STAR biomaterials can be customized, prototyped and fabricated to enhance the performance of your device or help you achieve your research objectives including in the areas of advanced wound care, aesthetic medicine, cardiovascular surgery, diabetes, general surgery, ophthalmology, pain management, regenerative medicine, urological/women’s health.